SWS Medical will make its debut at the ERA Congress 2026 from June 3-6 in Glasgow, welcoming nephrologists, industry leaders, and partners to showcase its next-generation blood purification solutions.

With integrated capabilities spanning R&D, manufacturing, and global distribution, SWS Medical continues to expand its international presence in dialysis and critical care blood purification. At ERA 2026, the company will showcase the next generation of dialysis and CRRT platforms designed to support intelligent automation, connected care, workflow efficiency, and integrated therapy delivery.

Featured technologies include the SWS-4000 and SWS-6000 series, among China's leading dialysis platforms, which together accounted for an estimated 20 per cent share of the country's dialysis machine market in 2025. The flagship SWS-6000 is the only dialysis machine in China with certified monitoring of key treatment parameters, while the SWS-4000 features an Online HDF system for sterile fluid production. Together, the platforms are designed to support safer, more efficient treatment through intelligent monitoring and automation.

The CE-certified SWS-5000, China's No. 1 CRRT machine for three consecutive years, is an award-winning all-in-one platform designed to support integrated multi-organ blood purification therapies across renal, hepatic, cardiac, pulmonary, and pancreatic applications.

The portfolio also includes advanced dialysers manufactured using proprietary pre-vacuum pressure steam sterilisation and 100 per cent BPA-free materials to deliver high solute clearance and reliable ultrafiltration performance, alongside dialysis fluid filters and hemoperfusion cartridges for expanded blood purification therapies.

Supporting the company's connected-care strategy, the Integrated Management Platform links dialysis centres, clinicians, and patients through the Data Hub, Patient Card, and Hemodialysis Management System, helping transform data into safer, smarter, care delivery.